M
Maribel Rodriguez-Torres
Researcher at San Juan Bautista School of Medicine
Publications - 138
Citations - 13678
Maribel Rodriguez-Torres is an academic researcher from San Juan Bautista School of Medicine. The author has contributed to research in topics: Ribavirin & Hepatitis C. The author has an hindex of 44, co-authored 137 publications receiving 13171 citations. Previous affiliations of Maribel Rodriguez-Torres include Consejo Nacional de Ciencia y Tecnología & Pontifical Catholic University of Puerto Rico.
Papers
More filters
Journal ArticleDOI
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
Eric Lawitz,Mark S. Sulkowski,Reem Ghalib,Maribel Rodriguez-Torres,Zobair M. Younossi,Ana Corregidor,Edwin DeJesus,Brian L. Pearlman,Mordechai Rabinovitz,Norman Gitlin,Joseph K. Lim,Paul J. Pockros,John D. Scott,Bart Fevery,Tom Lambrecht,Sivi Ouwerkerk-Mahadevan,Katleen Callewaert,William T. Symonds,Gaston Picchio,Karen L Lindsay,Maria Beumont,Ira M. Jacobson +21 more
TL;DR: Combined simeprevir and sofosbuvir was efficacious and well tolerated in chronic HCV genotype 1 infections and sustained virological response 12 weeks after stopping treatment was achieved.
Journal ArticleDOI
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
John G. McHutchison,Geoffrey Dusheiko,Mitchell L. Shiffman,Maribel Rodriguez-Torres,Samuel H. Sigal,M. Bourliere,Thomas Berg,Stuart C. Gordon,Fiona Campbell,Dickens Theodore,Nicole Jill-Marie Blackman,Julian Jenkins,Nezam H. Afdhal +12 more
TL;DR: Eltrombopag therapy increases platelet counts in patients with thrombocytopenia due to HCV-related cirrhosis, thereby permitting the initiation of antiviral therapy.
Journal ArticleDOI
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
Eric Lawitz,J. Lalezari,Tarek Hassanein,Kris V. Kowdley,Fred Poordad,Aasim Sheikh,Nezam H. Afdhal,David E. Bernstein,E. DeJesus,B. Freilich,David R. Nelson,Douglas T. Dieterich,Ira M. Jacobson,Donald M. Jensen,Gary A Abrams,Jama M. Darling,Maribel Rodriguez-Torres,K. Rajender Reddy,Mark S. Sulkowski,Natalie Bzowej,Robert H. Hyland,Hongmei Mo,Ming Lin,M. Mader,R. Hindes,Efsevia Albanis,William T. Symonds,M.M. Berrey,Andrew J. Muir +28 more
TL;DR: The findings lend support to the further assessment of sofosbuvir 400 mg plus peginterferon and ribavirin for 12 weeks in treatment-naive patients with HCV genotype-1, and sustained virological response, defined as undetectable HCV RNA at post-treatment weeks 12 and 24.
Journal ArticleDOI
Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.
Mark S. Sulkowski,Susanna Naggie,Jacob Lalezari,Walford Jeffrey Fessel,Karam Mounzer,Margaret C. Shuhart,Anne F Luetkemeyer,David M. Asmuth,Anuj Gaggar,Liyun Ni,Evguenia S. Svarovskaia,Diana M. Brainard,William T. Symonds,G. Mani Subramanian,John G. McHutchison,Maribel Rodriguez-Torres,Douglas T. Dieterich +16 more
TL;DR: Patients with HIV who were coinfected with HCV genotype 1, 2, or 3 who received the oral, interferon-free combination of sofosbuvir and ribavirin for 12 or 24 weeks had high rates of SVR12, the proportion of patients with SVR 12 12 weeks after cessation of HCV therapy.
Journal ArticleDOI
Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection
Gregory T. Everson,K. Sims,Maribel Rodriguez-Torres,Christophe Hézode,Eric Lawitz,Marc Bourlière,Véronique Loustaud-Ratti,Vinod K. Rustgi,Howard Schwartz,Harvey A Tatum,Patrick Marcellin,Stanislas Pol,Paul J. Thuluvath,Timothy Eley,Xiaodong Wang,Shu-Pang Huang,Fiona McPhee,Megan Wind-Rotolo,Ellen Chung,Claudio Pasquinelli,Dennis M. Grasela,David F. Gardiner +21 more
TL;DR: In a phase 2a study, the all-oral, interferon-free, and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 was well tolerated and achieved high rates of SVR12 in patients with HCV genotype 1 infection.